- Trials with a EudraCT protocol (62)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
62 result(s) found for: Hearing level.
Displaying page 1 of 4.
EudraCT Number: 2015-002602-36 | Sponsor Protocol Number: KKSH-127 | Start Date*: 2016-06-21 |
Sponsor Name:Martin-Luther-Universität Halle-Wittenberg | ||
Full Title: Efficacy and safety of high dose glucocorticosteroid treatment for idiopathic sudden sensorineural hearing loss (HODOKORT) | ||
Medical condition: Idiopathic sudden sensorineural hearing loss | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005741-17 | Sponsor Protocol Number: 76096 | Start Date*: 2021-08-25 |
Sponsor Name:Amsterdam University Medical Centers, location AMC | ||
Full Title: Hyperbaric OXygen therapy for ACute Acoustic Trauma | ||
Medical condition: Acute acoustic trauma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001509-25 | Sponsor Protocol Number: RHMCAN0860 | Start Date*: 2012-09-25 | |||||||||||
Sponsor Name:University Hospital Southampton NHS Foundation Trust | |||||||||||||
Full Title: COAST - Cisplatin Ototoxicity attenuated by Aspirin Trial A randomised, Phase II, double-blind, placebo-controlled, two arm Trial to establish whether Aspirin can reduce hearing loss/ototoxicity fo... | |||||||||||||
Medical condition: To establish whether Aspirin can reduce hearing loss/ototoxicity for patients receiving Cisplatin based chemotherapy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000079-38 | Sponsor Protocol Number: DB-OTO-001 | Start Date*: 2023-05-09 | |||||||||||
Sponsor Name:Decibel Therapeutics | |||||||||||||
Full Title: A Phase 1/2, Open-Label, Multicenter Trial With a Single Ascending Dose Cohort With Unilateral Intracochlear Injection Followed by a Bilateral Injection Expansion Cohort to Evaluate the Safety, Tol... | |||||||||||||
Medical condition: Congenital auditory neuropathy secondary to biallelic mutations of the otoferlin gene (hOTOF) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001527-39 | Sponsor Protocol Number: AM-101-CL-12-04 | Start Date*: 2013-11-21 | |||||||||||
Sponsor Name:Auris Medical AG | |||||||||||||
Full Title: AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 2 (AMPACT2) – an open-label extension to the TACTT3 study | |||||||||||||
Medical condition: Treatment of peripheral tinnitus following traumatic cochlear injury or otitis media | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Completed) DE (Completed) AT (Completed) GB (Completed) PL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002705-10 | Sponsor Protocol Number: SENS-401-202 | Start Date*: 2022-03-04 |
Sponsor Name:SENSORION PHARMA | ||
Full Title: An Exploratory, Phase IIa, Multicenter, Randomized, Controlled, Open label Study to Evaluate the Efficacy of SENS-401 to Prevent or Treat the Ototoxicity due to Cisplatin in Adult Subjects with a N... | ||
Medical condition: Cisplatin-induced hearing loss | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2013-002261-18 | Sponsor Protocol Number: M05-2013 | Start Date*: 2013-08-21 |
Sponsor Name:Synphora AB | ||
Full Title: A randomized, double-blind, placebo-controlled, parallel group study to determine the efficacy, the duration of action, and safety of latanoprost in patients with Menière’s disease | ||
Medical condition: Menière´s disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-003586-45 | Sponsor Protocol Number: Painscales_Sedation_1 | Start Date*: 2009-09-24 |
Sponsor Name:Department of Anaesthesie, General Intensive Care and Pain Therapy | ||
Full Title: The precision of three pain scales as a function of sedation | ||
Medical condition: This is a patient study in patients with a planned operation under general anaesthesie including healthy or merately ill patients (anaesthesia risk classification ASA 1-3). Pain self assessment as ... | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-022085-26 | Sponsor Protocol Number: rhLAMAN-03 | Start Date*: 2010-10-05 |
Sponsor Name:Zymenex A/S | ||
Full Title: A single center, randomized, open-label, multiple-dose study of the efficacy and long-term safety of rhLAMAN (recombinant human alpha-mannosidase or Lamazym) for the treatment of patients with alph... | ||
Medical condition: Treatment of alpha-Mannosidosis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-000156-35 | Sponsor Protocol Number: NF2PET | Start Date*: 2021-03-18 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: 89Zr-Bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic neurofibromatosis type 2. | ||
Medical condition: Neurofibromatosis type 2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002223-28 | Sponsor Protocol Number: PHAO14-CH/TEPTAU | Start Date*: 2016-11-30 |
Sponsor Name:CHRU DE TOURS | ||
Full Title: Tau brain imaging in typical and atypical Alzheimer’s Disease (AD) | ||
Medical condition: Alzheimer's diseases | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002888-18 | Sponsor Protocol Number: CHAVANET-PHRC-2016 | Start Date*: 2018-01-16 | |||||||||||
Sponsor Name:CHU Dijon Bourgogne | |||||||||||||
Full Title: Adjunction of daptomycin for the treatment of pneumococcal meningitis AddaMAP study | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004099-20 | Sponsor Protocol Number: AM-101-CL-12-02 | Start Date*: 2013-10-30 | |||||||||||
Sponsor Name:Auris Medical AG | |||||||||||||
Full Title: Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 3 (TACTT3) | |||||||||||||
Medical condition: acute peripheral tinnitus following traumatic cochlear injury or otitis media | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Completed) DE (Completed) AT (Completed) GB (Completed) PL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004594-43 | Sponsor Protocol Number: ISTEM02 | Start Date*: 2021-05-27 | |||||||||||
Sponsor Name:CECS/I-Stem | |||||||||||||
Full Title: AUDIOWOLF: A phase II, open-label, efficacy study of daily administration of sodium valproate in patients clinically affected by Wolfram syndrome due to monogenic mutation | |||||||||||||
Medical condition: Wolfram syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001777-86 | Sponsor Protocol Number: 91710346.1.2 | Start Date*: 2012-10-23 |
Sponsor Name: | ||
Full Title: Pilot study for classification of attempted movement from the electroencephalogram in healthy participants with a temporary paralysis of one arm induced by local administration of rocuronium | ||
Medical condition: Intraoperative awareness during general anesthesia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-002314-17 | Sponsor Protocol Number: JR-441-101 | Start Date*: 2023-07-03 | |||||||||||
Sponsor Name:JCR Pharmaceuticals Co., Ltd. | |||||||||||||
Full Title: Phase I/II study of weekly infusions of JR-441 in patients with mucopolysaccharidosis type IIIA | |||||||||||||
Medical condition: Mucopolysaccharidosis type IIIA (MPS IIIA) MPS III is an autosomal recessive disease characterized by the accumulation of HS in the tissues throughout the body due to a deficiency in enzymes involv... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001401-41 | Sponsor Protocol Number: TAPAS-2014 | Start Date*: 2014-07-29 |
Sponsor Name: | ||
Full Title: Targeting Antibiotics to Pseudomonas Aeruginosa in Small airways (TAPAS) study in patients with cystic fibrosis | ||
Medical condition: Cystic Fibrosis and chronic infection with Pseudomonas aeruginosa | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-002885-38 | Sponsor Protocol Number: HGT-HIT-094 | Start Date*: 2013-10-22 | |||||||||||
Sponsor Name:Shire HGT Inc | |||||||||||||
Full Title: A Controlled,Randomized,Two-arm,Open-label,Assessor-blinded,Multicenter Study of Intrathecal Idursulfase-IT Administered in Conjunction with Elaprase® in Pediatric Patients with Hunter Syndrome and... | |||||||||||||
Medical condition: Long-term treatment of Hunter syndrome and cognitive impairment | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-006174-97 | Sponsor Protocol Number: BST22006 | Start Date*: 2007-05-02 |
Sponsor Name:University of Oxford, Research Governance & Clinical Trials Office | ||
Full Title: Which oxygen saturation level should we use for very premature infants? A randomised controlled trial (BOOST-II UK) | ||
Medical condition: Respiratory distress of newborn ICD codes P22.0, P22.8, P22.9 | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) IE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-003929-34 | Sponsor Protocol Number: AUT042063 | Start Date*: 2016-03-10 | |||||||||||
Sponsor Name:Autifony Therapeutics Limited | |||||||||||||
Full Title: A Pilot Double-blind, Placebo-controlled Crossover Study to Explore the Possible Benefit of AUT00063, an Oral Modulator of Voltage-gated Potassium Channels, in Adult Post-lingual Unilateral Cochlea... | |||||||||||||
Medical condition: Impaired speech understanding in users of cochlear implants | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
